Pharmacological Rationale for the Clinical Use of Caffeine
- 1 January 1995
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 49 (1) , 37-50
- https://doi.org/10.2165/00003495-199549010-00004
Abstract
Caffeine is widely consumed in beverages to obtain mild CNS stimulant effects. Long term use produces tolerance to some of the pharmacological effects. Withdrawal of caffeine, even from moderate intake levels, can produce symptoms such as headache, fatigue and anxiety. Caffeine is used therapeutically in combination with ergotamine for migraine headaches and in combination with nonsteroidal anti-inflammatory drugs in analgesic formulations. Caffeine alone is used as a somnolytic, to treat various headache conditions, respiratory depression in neonates, postprandial hypotension and obesity, and to enhance seizure duration in electroconvulsive therapy. In some headache and in pain paradigms, caffeine may produce direct adjuvant analgesic properties, while in other headache conditions (perioperative, post-dural puncture) caffeine may be effective by alleviating a manifestation of caffeine withdrawal. Other uses, such as to promote wakefulness, for respiratory stimulation and seizure prolongation, rely on central stimulant properties of caffeine. Effects of caffeine on the vasculature may contribute to the relief of some headaches and in postprandial hypotension. Blockade of methylxanthinesensitive adenosine receptors is the currently accepted mechanism of action of caffeine.Keywords
This publication has 97 references indexed in Scilit:
- SumatriptanDrugs, 1992
- Caffeine and human cerebral blood flow: A positron emission tomography studyLife Sciences, 1990
- Caffeine and theophylline analogues: Correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitorsLife Sciences, 1988
- Theophylline versus caffeine: Comparative effects in treatment of idiopathic apnea in the preterm infantThe Journal of Pediatrics, 1987
- Cross-tolerance studies between caffeine and (−)-N6-(phenylisopropyl)-adenosine (PIA) in miceLife Sciences, 1986
- Caffeine tolerance: Behavioral, electrophysiological and neurochemical evidenceLife Sciences, 1985
- Clinical Pharmacokinetics of Ergotamine in Migraine and Cluster HeadacheClinical Pharmacokinetics, 1985
- Chronic caffeine consumption increases the number of brain adenosine receptorsLife Sciences, 1983
- Purinergic inhibition of diazepam binding to rat brain ()Life Sciences, 1979
- Efficacy of caffeine in treatment of apnea in the low-birth-weight infantThe Journal of Pediatrics, 1977